Interna, Daiichi Sankyo Partner on Drug Delivery Tech

PETACH TIKVA, Israel, April 16, 2026

Interna Therapeutics has announced a strategic research collaboration with Daiichi Sankyo to advance its Molecular Nano Motor (MNM) intracellular delivery platform, aiming to enhance the precision, efficiency, and performance of targeted therapeutic modalities. The partnership reflects growing industry demand for next-generation drug delivery technologies capable of overcoming one of the most critical challenges in modern drug development—efficient intracellular delivery of therapeutic agents.

Collaboration Focuses on Advanced Intracellular Delivery

Under the terms of the agreement, the collaboration will focus on integrating Interna’s MNM molecules with advanced targeting strategies to improve intracellular delivery, functional activity, and therapeutic performance across selected research programs. The initiative will begin with preclinical evaluation, providing a foundation for potential expansion into broader research and additional therapeutic programs based on successful outcomes.

The collaboration framework allows both companies to explore how MNM technology can enhance drug targeting precision and cellular uptake, particularly for complex therapeutic modalities such as nucleic acids and biologics. By addressing intracellular delivery barriers, the partnership aims to unlock higher efficacy and improved clinical outcomes across multiple disease areas.

This agreement also strengthens Interna’s position within the biopharma ecosystem, highlighting increasing interest from global pharmaceutical leaders in innovative delivery platforms that can complement existing drug pipelines.

MNM Platform Enables Breakthrough Drug Delivery Innovation

Interna’s proprietary Molecular Nano Motor (MNM) platform represents a novel approach to intracellular delivery, designed to transport therapeutic cargo directly into cells without relying on traditional delivery systems such as viral vectors or lipid nanoparticles. This technology enables efficient penetration into target tissues and enhanced intracellular access, which are critical for therapies involving siRNA, mRNA, and other macromolecules.

The MNM platform has the potential to significantly improve the performance of targeted therapies by ensuring that active compounds reach their intended intracellular targets with greater accuracy and consistency. This capability is particularly important in emerging therapeutic areas such as gene therapy, RNA therapeutics, and precision medicine, where delivery efficiency directly impacts treatment success.

By combining MNM technology with Daiichi Sankyo’s expertise in drug discovery and targeted therapies, the collaboration aims to create synergistic advancements in therapeutic design and delivery, potentially leading to next-generation treatments with improved safety and efficacy profiles.

Strategic Impact on Biopharma Innovation

The collaboration between Interna Therapeutics and Daiichi Sankyo reflects a broader trend in the biopharma industry toward strategic partnerships focused on enabling technologies, particularly those that address key bottlenecks in drug development. Intracellular delivery remains one of the most significant challenges in translating promising therapies into clinically effective treatments, and solutions like MNM are increasingly seen as critical to advancing the field.

By focusing on preclinical validation and scalable technology integration, the partnership aligns with GxP-compliant development practices, ensuring that innovations can be translated into clinical and commercial applications. The collaboration also provides a pathway for expanding into multiple therapeutic areas, including respiratory diseases and central nervous system disorders, where effective delivery remains a major hurdle.

Furthermore, the agreement demonstrates how platform technologies are becoming central to pharmaceutical innovation, enabling companies to enhance existing drug candidates and accelerate the development of new therapies. As the industry continues to evolve, such collaborations are expected to play a key role in shaping the future of precision medicine and targeted treatment approaches.

Implications for Future Therapeutic Development

The integration of MNM technology into targeted therapeutic programs could significantly impact the development of next-generation biologics and nucleic acid-based therapies, offering improved delivery efficiency and clinical performance. By enabling more effective intracellular access, the technology has the potential to expand the range of treatable conditions and improve outcomes for patients with complex diseases.

As the collaboration progresses, successful outcomes could lead to broader partnerships, expanded research programs, and potential clinical applications, positioning Interna Therapeutics as a key innovator in the field of drug delivery.

The Interna Therapeutics and Daiichi Sankyo collaboration represents a strategic advancement in intracellular delivery technology, combining cutting-edge innovation with global pharmaceutical expertise to address one of the most critical challenges in drug development. With its potential to enhance therapeutic precision, efficacy, and scalability, the MNM platform is poised to play a significant role in the future of biopharma innovation and targeted therapy development.

Source: Interna Therapeutics, Daiichi Sankyo press release